Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis

References

• Araújo, A. M., F. Carvalho, M. L. de Bastos, P. Guedes de Pinho, and M. Carvalho. 2015. The hallucinogenic world of tryptamines: An updated review. Archives Toxicogical 89:1151–73. doi:10.1007/s00204-015-1513-x.
   PubMed Web of Science ®Google Scholar
• Bersani, F. S., O. Corazza, G. Albano, G. Valeriani, R. Santacroce, F. Bolzan Mariotti Posocco, E. Cinosi, P. Simonato, G. Martinotti, G. Bersani, and F. Schifano. 2014. 25C-NBOMe: Preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomedical Researcher International 2014:734749. doi:10.1155/2014/734749.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P. 2013. Studying the effects of classic hallucinogens in the treatment of alcoholism: Rationale, methodology, and current research with psilocybin. Current Drug Abuse Reviews 6:17–29. doi:10.2174/15733998113099990002.
   PubMedGoogle Scholar
• Bruno, R., A. J. Matthews, M. Dunn, R. Alati, F. McIlwraith, S. Hickey, L. Burns, and N. Sindicich. 2012. Emerging psychoactive substance use among regular ecstasy users in Australia. Drug and Alcohol Dependence 124:19–25. doi:10.1016/j.drugalcdep.2011.11.020.
   PubMed Web of Science ®Google Scholar
• Caudevilla-Gálligo, F., J. Riba, M. Ventura, D. González, M. Farré, M. J. Barbanoj, and J. C. Bouso. 2012. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): Presence in the recreational drug market in Spain, pattern of use and subjective effects. Journal Psychopharmacology 26:1026–35. doi:10.1177/0269881111431752.
   PubMed Web of Science ®Google Scholar
• Caudevilla-Gálligo, F., M. Ventura, B. I. Indave Ruiz, and I.Fornís. 2013. Presence and composition of cathinone derivatives in drug samples taken from a drug test service in Spain (2010–2012). Human Psychopharmacology 28:341–44. doi:10.1002/hup.2296.
   PubMed Web of Science ®Google Scholar
• Corkery, J. M., E. Durkin, S. Elliott, F. Schifano, and A. H. Ghodse. 2012. The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): A brief review. Progress in Neuro-Psychopharmacology & Biological Psychiatry 39:259–62. doi:10.1016/j.pnpbp.2012.05.022.
   PubMed Web of Science ®Google Scholar
• De Osório, F. L., R. F. Sanches, L. R. Macedo, R. G. Santos, J. P. Maia-de-Oliveira, L. Wichert-Ana, D. B. Araujo, J. Riba, J. A. Crippa, and J. E. Hallak. 2015. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Reviews Bras Psiquiatr 37:13–20. doi:10.1590/1516-4446-2014-1496.
   PubMed Web of Science ®Google Scholar
• EMCDDA. 2015. New psychoactive substances in Europe: An update from the EU Early Warning System. Lisbon, Portugal: EMCDDA.
   Google Scholar
• Farré, M., L. Galindo, and M. Torrens. 2015. Addiction to hallucinogens, dissociatives, designer drugs and “legal highs” on textbook of addiction treatment: International perspectives, vol. 2, chapter 27, 567–96. Berlin, Germany: Springer.
   Google Scholar
• Giné, C. V., I. F. Espinosa, and M. V. Vilamala. 2014. New psychoactive substances as adulterants of controlled drugs: A worrying phenomenon? Drug Testing Analysis 6:819–24. doi:10.1002/dta.1610.
   PubMed Web of Science ®Google Scholar
• González, D., M. Ventura, F. Caudevilla, M. Torrens, and M. Farre. 2013. Consumption of new psychoactive substances in a Spanish sample of research chemical users. Human Psychopharmacology 28:332–40. doi:10.1002/hup.2323.
   PubMed Web of Science ®Google Scholar
• Hill, S. L., and S. H. L. Thomas. 2015. Clinical toxicology of newer recreational drugs. Clinical Toxicology 49:705–19. doi:10.3109/15563650.2011.615318.
   Web of Science ®Google Scholar
• Hondebrink, L., J. J. Nugteren-van Lonkhuyzen, D. Van Der Gouwe, and T. M. Brunt. 2015. Monitoring new psychoactive substances (NPS) in The Netherlands: Data from the drug market and the Poisons Information Centre. Drug and Alcohol Dependence 147:109–15. doi:10.1016/j.drugalcdep.2014.11.033.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, M. P. Cosimano, and R. R. Griffiths. 2014. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal Psychopharmacology 28:983–92. doi:10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Kamour, A., D. James, R. Spears, G. Cooper, D. J. Lupton, M. Eddleston, J. P. Thompson, A. J. Vale, H. K. Thanacoody, S. L. Hill, and S. H. Thomas. 2014. Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom: A report from the UK National Poisons Information Service. Clinical Toxicogical (Phila) 52:192–97. doi:10.3109/15563650.2014.885983.
   PubMed Web of Science ®Google Scholar
• Lessin, A. W., R. F. Long, and M. W. Parkes. 1965. Central stimulant actions of alpha-alkyl substituted tryptamines in mice. British Journal Pharmacology Chemotherapy 24:49–67. doi:10.1111/j.1476-5381.1965.tb02079.x.
   PubMed Web of Science ®Google Scholar
• Maxwell, J. C. 2014. Psychoactive substances–some new, some old: A scan of the situation in the U.S. Drug and Alcohol Dependence 134:71–77. doi:10.1016/j.drugalcdep.2013.09.011.
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad, Servicios Sociales e Igualdad. 2015. BOE núm. 274, de 16 de noviembre de 1977. Referencia: BOE-A-1977-27160. Última modificación: 12 de junio de 2015.
   Google Scholar
• Ministerio de Sanidad, Servicios Sociales e Igualdad. 2015. Delegación del gobierno para el plan nacional sobre drogas. Encuesta sobre alcohol y drogas en población general en España (EDADES) 2013. Madrid, Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad.
   Google Scholar
• Morano, R. A., C. Spies, F. B. Walker, and S. M. Plank. 1993. Fatal intoxication involving etryptamine. Journal of Forensic Sciences 38:721–25. doi:10.1520/JFS13461J.
   PubMed Web of Science ®Google Scholar
• Palamar, J. J., S. S. Martins, M. K. Su, and D. C. Ompad. 2015. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug and Alcohol Dependence 156:112–19. doi:10.1016/j.drugalcdep.2015.08.028.
   PubMed Web of Science ®Google Scholar
• Sanders, B., S. E. Lankenau, J. J. Bloom, and D. Hathazi. 2008. “Research chemicals”: Tryptamine and phenethylamine use among high-risk youth. Substance Use & Misuse 43:389–402. doi:10.1080/00952990701202970.
   PubMed Web of Science ®Google Scholar
• Sessa, B., and M. W. Johnson. 2015. Can psychedelic compounds play a part in drug dependence therapy? British Journal Psychiatry 206:1–3. doi:10.1192/bjp.bp.114.148031.
   PubMed Web of Science ®Google Scholar
• Shen, H.-W., X.-L. Jiang, J. C. Winter, and A.-M. Yu. 2010. Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Current Drug Metabolism 11:659–66. doi:10.2174/138920010794233495.
   PubMed Web of Science ®Google Scholar
• Sklerov, J., B. Levine, K. A. Moore, T. King, and D. Fowler. 2005. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. Journal Analysis Toxicogical 29:838–41. doi:10.1093/jat/29.8.838.
   PubMed Web of Science ®Google Scholar
• Sogawa, C., N. Sogawa, J. Tagawa, A. Fujino, K. Ohyama, M. Asanuma, M. Funada, and S. Kitayama. 2007. 5-Methoxy-N,N-diisopropyltryptamine (foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicology Letters 170:75–82. doi:10.1016/j.toxlet.2007.02.007.
   PubMed Web of Science ®Google Scholar
• Tanaka, E., T. Kamata, M. Katagi, H. Tsuchihashi, and K. Honda. 2006. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, foxy. Forensic Science International 163:152–54. doi:10.1016/j.forsciint.2005.11.026.
   PubMed Web of Science ®Google Scholar
• Tittarelli, R., G. Mannocchi, F. Pantano, and F. S. Romolo. 2015. Recreational use, analysis and toxicity of tryptamines. Current Neuropharmacol 13:26–46. doi:10.2174/1570159X13666141210222409.
   PubMed Web of Science ®Google Scholar
• The Vaults of Erowid. 2016. 4-Acetoxy-DET. The Vaults of Erowid. https://www.erowid.org/chemicals/4_acetoxy_det/4_acetoxy_det.shtml ( accessed July 2016).
   Google Scholar
• The Vaults of Erowid. 2016. 4-Acetoxy-DiPT. The Vaults of Erowid. https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml ( accessed July 2016).
   Google Scholar
• The Vaults of Erowid. 2016. 4-Acetoxy-DMT. https://www.erowid.org/chemicals/4_acetoxy_dmt/4_acetoxy_dmt.shtml ( accessed July 2016).
   Google Scholar
• The Vaults of Erowid. 2016. 4-Acetoxy-MiPT. https://www.erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml ( accessed July 2016).
   Google Scholar
• UNODC (United Nations Office on Drugs and Crime). 2013. The challenge of new psychoactive substances: A report from the Global SMART Programme. Vienna, Austria: United Nations Office on Drugs and Crime.
   Google Scholar
• Weil, A. T., and W. Davis. 1994. Bufo alvarius: A potent hallucinogen of animal origin. Journal Ethnopharmacol 41:1–8. doi:10.1016/0378-8741(94)90051-5.
   PubMed Web of Science ®Google Scholar
• Wilson, J. M., F. McGeorge, S. Smolinske, and R. Meatherall. 2005. A foxy intoxication. Forensic Science International 148:31–36. doi:10.1016/j.forsciint.2004.04.017.
   PubMed Web of Science ®Google Scholar
• Winkelman, M. 2014. Psychedelics as medicines for substance abuse rehabilitation: Evaluating treatments with LSD, peyote, ibogaine and ayahuasca. Current Drug Abuse Reviews 7:101–16. doi:10.2174/1874473708666150107120011.
   PubMedGoogle Scholar
• Winstock, A. R., S. Kaar, and R. Borschmann. 2014. Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. Journal Psychopharmacology 28:49–54. doi:10.1177/0269881113513852.
   PubMed Web of Science ®Google Scholar
• Young, S. N. 2013. Single treatments that have lasting effects: Some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. Journal Psychiatry Neuroscience 38:78–83. doi:10.1503/jpn.
   PubMed Web of Science ®Google Scholar